Impact News +++ Stimmrechtsanteile News: Adtran Holdings, Inc. (EQS) +++ ADTRAN Aktie +5,17%

Gewinn & Umsatz News zur TEVA Aktie

>TEVA Aktienkurs

29.7 EUR -0.3% (TradegateBSX)

Ask: 29.8 EUR / 3000 Stück

Bid: 29.7 EUR / 3000 Stück

Tagesumsatz: 12639 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

TEVA Aktie über LYNX handeln

Intraday

1 Jahr

>TEVA Performance

1 Woche: +1,4%

1 Monat: +14,6%

3 Monate: +4,9%

6 Monate: +31,1%

1 Jahr: +95,4%

laufendes Jahr: +11,2%

>TEVA Aktie

Name:

TEVA PHARMACEUTICAL INDUSTRIES ADR

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US8816242098 / 883035

Symbol/ Ticker:

TEV (Frankfurt) / TEVA (NYSE)

Kürzel:

FRA:TEV, ETR:TEV, TEV:GR, NYSE:TEVA

Index:

Webseite:

https://www.tevapharm.com..

Profil:

Teva Pharmaceutical Industries Ltd. ADR is an American Depositary Receipt representing shares of the Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd., founded in 1901 and headquartered in Tel Aviv, Israel. The company develops,..
>Volltext..

Marktkapitalisierung:

35260.94 Mio. EUR

Unternehmenswert:

46576.09 Mio. EUR

Umsatz:

15058.43 Mio. EUR

EBITDA:

4361.48 Mio. EUR

Nettogewinn:

1352.38 Mio. EUR

Gewinn je Aktie:

1.18 EUR

Schulden:

14525.83 Mio. EUR

Liquide Mittel:

3214.12 Mio. EUR

Operativer Cashflow:

Bargeldquote:

0.28

Umsatzwachstum:

5.76%

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Div. Historie:

27.11.17 - 0.07293€
25.08.17 - 0.07293€

>weitere anzeigen...

Insiderhandel:

6 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 14.181.924 USD.

Suchwörter:

TEVA

Letzte Datenerhebung:

27.05.26

>TEVA Kennzahlen

Aktien/ Unternehmen:

Aktien: 1164.64 Mio. St.

Frei handelbar: 99.99%

Leerverk. Aktien: 2.67%

Rückkaufquote: -

Mitarbeiter: 33346

Umsatz/Mitarb.: 0.45 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 20.32%

Bewertung:

KGV: 26.01

KGV lG: 15.52

KUV: 2.29

KBV: 4.95

PEG-Ratio: -

EV/EBITDA: 10.68

Rentabilität:

Bruttomarge: 52.19%

Gewinnmarge: 8.98%

Operative Marge: 23.22%

Managementeffizenz:

Gesamtkaprendite: 4.01%

Eigenkaprendite: 21.73%

>TEVA Anleihen

>TEVA Peer Group

Gesundheit, Medizin für Bakterielle- & Pilzinfektionen/ Antibiotika, Multiple Sklerose- Behandlung, Neurologie/ psychische Behandlung/ Schlaganfälle, Medizinprodukte & -technik/ Implantate/ Wundpflege
>Alle Branchen..

>TEVA Chart & Kurs - NYSE

>TEVA Gewinn & Umsatz News

29.04.26 - 14:30	Teva Lowers 2026 Non-GAAP Operating Profit Outlook On Emalex Deal; On Track To Achieve 2027 Targets (AFX)
	PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries (TEVA) said, for 2026, non-GAAP operating income is now projected in a range of $3.80 - $4.0 billion, revised from $4.55 - $4.8 billion stand......

29.04.26 - 14:18	Teva Rises After Sales Top Estimates on Shift to Branded Drugs (Bloomberg)
	Generic drug manufacturer Teva Pharmaceuticals Inc. beat Wall Street estimates on Wednesday for the first quarter on demand for its branded medications....

17.02.26 - 15:42	Sanofi, Teva Report Positive Phase 2b Results For Duvakitug (AFX)
	PARIS (dpa-AFX) - Sanofi SA (SNY) and Teva Pharmaceutical Industries Ltd. (TEVA) reported on Tuesday, positive long-term extension data from the phase 2b RELIEVE UCCD study of duvakitug in ulcerat......

28.01.26 - 14:12	Teva sees lower revenue and profit in 2026 (Globes)
	After three consecutive years of growth, the Israeli pharmaceutical company predicts a small decline this year....

28.01.26 - 13:54	Teva Slumps as 2026 Revenue Outlook Falls Short of Expectations (Bloomberg)
	Teva Pharmaceuticals Inc. fell Wednesday after its 2026 revenue forecast was weaker than Wall Street expected....

28.01.26 - 13:54	Teva Pharmaceutical Turns To Profit In Q4, Announces FY26 Outlook (AFX)
	PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Limited (TEVA), Wednesday announced the fourth quarter financial results, reporting net profit of $480 million, or $0.41 per share, attributa......

06.12.25 - 16:42

Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue (24/7 Wall St.)

Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two pharmaceutical companies moving in opposite directions. Pfizer is stabilizing after its COVID revenue collapse while Teva is accelerating through an innovation-led turnaround that has delivered 11 consecutive quarters of growth. One Declining, One Accelerating Pfizer posted Q3 revenue of ... Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue The post Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue appeared first on 24/7 Wall St.....

05.11.25 - 21:24	Teva Hits Highest Since 2018 as 3Q Revenue Beats Estimates (Bloomberg)
	Teva Pharmaceutical CEO Richard Francis speaks about 3Q earnings on Bloomberg BusinessWeek with Bloomberg's Katie Greifeld and Emily Graffeo. (Source: Bloomberg)...

05.11.25 - 14:06	Teva Surges After Push Into Branded Drugs Drives Sales Beat (Bloomberg)
	Teva Pharmaceuticals Inc. surged after sales of branded medications topped expectations, showing that its strategy to expand into that drug category is working....

05.11.25 - 13:54	Teva Pharma Boosts FY25 Adj. EPS Outlook As Q4 Results Top Estimates; Shares Up 9% (AFX)
	PETAH TIKVA (dpa-AFX) - While reporting financial results for the third quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) raised its adjusted earnings guidance for the full-year 2025......

03.11.25 - 16:54	Teva jumps ahead of Q3 results (Globes)
	Since the stock’s low-point in 2025 in April, the Israeli pharmaceutical company’s share price has risen over 60%....

30.07.25 - 14:06	Teva again raises profit guidance (Globes)
	The Israeli pharmaceutical company beat the analysts on profit but missed on revenue in the second quarter of 2025....

22.05.25 - 23:18	Deckers Outlook Misses Expectations as Tariffs, Slowing Hoka Sales Apply Pressure (WSJ EN)
	The footwear company, which also owns Ugg and Teva, said it wouldn't share an outlook for fiscal-year 2026, citing macroeconomic uncertainties. Shares fell in after-hours trading....

07.05.25 - 14:01	ROUNDUP: Teva Pharma Boosts FY25 Adj. EPS Outlook (AFX)
	PETAH TIKVA (dpa-AFX) - While reporting financial results for the first quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) raised its adjusted earnings guidance for the full-year 2025......

07.05.25 - 13:39	Teva Pharm first-quarter profit rise tops estimates (Reuters EN)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: O, der Einfall war kindisch, aber göttlich schön! - Friedrich Johann Christoph Schiller

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram